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Long-term viability and 
function of transplanted islets 
macroencapsulated at high density 
are achieved by enhanced oxygen 
supply
Yoav Evron1, Clark K. Colton2, Barbara Ludwig3, Gordon C. Weir4, Baruch Zimermann1,  
Shiri Maimon1, Tova Neufeld1, Nurit Shalev1, Tali Goldman1, Assaf Leon1, Karina Yavriyants1, 
Noa Shabtay1, Tania Rozenshtein1, Dimitri Azarov1, Amanda R. DiIenno2, Anja Steffen3,  
Paul de Vos5, Stefan R. Bornstein3, Uriel Barkai1 & Avi Rotem1
Transplantation of encapsulated islets can cure diabetes without immunosuppression, but oxygen 
supply limitations can cause failure. We investigated a retrievable macroencapsulation device 
wherein islets are encapsulated in a planar alginate slab and supplied with exogenous oxygen from 
a replenishable gas chamber. Translation to clinically-useful devices entails reduction of device 
size by increasing islet surface density, which requires increased gas chamber pO2. Here we show 
that islet surface density can be substantially increased safely by increasing gas chamber pO2 to a 
supraphysiological level that maintains all islets viable and functional. These levels were determined 
from measurements of pO2 profiles in islet-alginate slabs. Encapsulated islets implanted with surface 
density as high as 4,800 islet equivalents/cm3 in diabetic rats maintained normoglycemia for more than 
7 months and provided near-normal intravenous glucose tolerance tests. Nearly 90% of the original 
viable tissue was recovered after device explantation. Damaged islets failed after progressively shorter 
times. The required values of gas chamber pO2 were predictable from a mathematical model of oxygen 
consumption and diffusion in the device. These results demonstrate feasibility of developing retrievable 
macroencapsulated devices small enough for clinical use and provide a firm basis for design of devices 
for testing in large animals and humans.
Islet transplantation can functionally cure Type 1 diabetes but requires immunosuppression. Islet encapsula-
tion has promise for eliminating immunosuppression, but improvements in performance are needed1. Foremost 
amongst the outstanding problems is oxygen supply limitation2, which is a primary cause of failure. Donor islets 
are isolated from pancreatic tissue by enzymatic and mechanical processing, which disrupts their blood supply. 
Transplanted islets rely solely on diffusion for oxygen and nutrient supply, secretion of hormones, and removal of 
waste products. Oxygen is the first species to become diffusion limited3. Oxygen limitations occur in naked islets 
and in islets encapsulated in capsules or in retrievable macroencapsulation devices of various configurations and 
have been investigated with theoretical models and observed by experimental measurements2. Protection of islets 
from the host immune system by encapsulation aggravates the problem and further impairs islet viability and 
function. In addition, hypoxia followed by cell necrosis intensifies the immune response to transplanted tissue4.
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Various approaches have been studied to enhance oxygen supply to encapsulated islets and other therapeutic 
cells: (1) reduction of diffusion distances in the device and islet tissue; (2) increase of the oxygen permeabil-
ity of encapsulating material; (3) induction of neovascularization adjacent to the immunobarrier device with 
angiogenic proteins or vascularizing membranes to bring blood flow close to the tissue; and (4) provision of 
exogenous oxygen to produce a direct increase in oxygen concentration adjacent to the encapsulated tissue (2). 
Previous methods for providing exogenous oxygen include continuous local oxygen generation by in situ water 
electrolysis5,6 or photosynthesis7,8 or transient generation by hydrolytically-activated decomposition of solid per-
oxides9. We have used a simpler approach with a macroencapsulation device designed to enhance the supply of 
oxygen to the implanted islets while protecting the islets from immune attack. The device contained islets immo-
bilized within a flat alginate slab overlain by immunobarriers that prevent or minimize the cellular and humoral 
immune response to donor tissue. The slab was supplied with oxygen by diffusion through an oxygen-permeable 
membrane from a gas mixture in an adjacent chamber replenished daily through an externalized port. In pre-
vious work, devices containing either isogeneic or allogeneic islets immobilized at relatively low surface density 
(as low as about 1,400 IEQ/cm2 with air in the gas chamber) achieved normoglycemia in diabetic rats10,11, as 
did xenogeneic islets in minipigs12. A very low, sub-clinical dose of allogeneic human islets produced persis-
tent graft function in a human with regulated insulin secretion and preservation of islet morphology without 
immunosuppression13.
To translate these findings to regular clinical application, we aimed to minimize device size. Because the en 
face surface area required is inversely proportional to islet surface density (IEQ/cm2) that can be supported, our 
goal was to increase density by increasing oxygen partial pressure (pO2) in the internal gas chamber. We hypoth-
esized that higher islet surface density can be achieved without damage from exposure to high pO26 by using the 
minimum chamber pO2 required to support islets furthest away from the chamber. As O2 diffuses radially inward 
and is consumed by cells in an islet, its concentration decreases. For a spherical human islet equivalent (IEQ) con-
taining 1,560 cells14 and a 150-μm diameter, the outer islet surface should be at an oxygen partial pressure (pO2) 
of about 45–50 mmHg to maintain full functionality of all beta cells throughout the islet2,15–17.
Here we show that a density of 4,800 IEQ/cm2 for islets within the alginate slab of the device can be achieved 
by increasing oxygen concentration in the gas chamber to p02 > 300 mmHg, thereby enabling the use of a much 
smaller device for implantation. pO2 profiles measured in the slab in vitro were used to determine the minimum 
gas chamber pO2 that maintains the local bulk pO2 ≥ 50 mmHg throughout the slab at all times. These data were 
consistent with prediction of gas chamber pO2 from a simplified mathematical model describing oxygen diffusion 
and consumption in the slab. The required conditions were used in isogeneic implantations in diabetic rats with 
densities ranging up to about 4,800 IEQ/cm2 at constant islet loading of about 2,400 + 200 IEQ. Animals remained 
normoglycemic after implant periods ranging up to 229 days before elective termination. Intravenous glucose 
tolerance tests were comparable to those of nondiabetic animals, and oxygen consumption rate (OCR) measure-
ments with islet slabs revealed that explanted islets retained an average of 88% of their pre-implantation value, 
thereby demonstrating that the transplanted islets retained their viability and function over long periods of 
implantation. Lastly, duration of normoglycemia correlated with generalized islet quality assessment parameters 
in a manner similar to that obtained with naked rat islet transplants in mice. These data demonstrate that little 
islet damage was incurred by use of elevated pO2 in the gas chamber over the range studied, and the results pro-
vide a firm basis for the design and application of devices in future large animal and clinical studies.
Results
One device design was used in all experiments reported here. Islets were immobilized in a disc-like alginate slab 
that was mechanically reinforced by metal grids and was bounded by a microporous membrane on its outer 
face and a gas-permeable membrane on its inner face. This islet compartment (Fig. 1A) formed part of the outer 
surface of a disc-shaped structure, named the βAir device (Fig. 1B) that contained a gas chamber with two ports 
connected to remote subcutaneous access ports through which gas mixtures containing oxygen were replenished 
daily. The number of islets and the thickness of the islet compartment were maintained within small ranges, and 
we varied the islet surface density by changing the diameter of the islet compartment (Fig. 1C). With increas-
ing surface density, randomly scattered islets occupied an increasing fraction of the available space but retained 
their individual identity as single islets or as islets in more concentrated clusters (Fig. 1D). After explantation, 
islet-alginate slabs retained their initial appearance, intact and without visible damage or cracks in the alginate. 
With immunohistological examination, islets appeared normal with cells stained for insulin or glucagon as pre-
viously described10.
pO2 profile in islet-alginate slab. To determine conditions that assured all islets were exposed to an average 
pO2 of about 50 mmHg or more, we used an in vitro test system (Fig. 1E) to measure the pO2 profile across the slab 
by introducing an O2 electrode to sequentially increasing depths within the slab. Figure 1F shows a representative 
trace of the microelectrode output (left panel) and the pO2 profile within the slab (right panel) following purging 
of the gas chamber with a gas mixture having a pO2 of 304 mmHg while the space above the medium overlying 
the islet slab was continuously purged with O2 and CO2, both at a concentration of 40 mmHg and the balance N2. 
After each incremental advance of the electrode, steady state was achieved in less than 30 s, and pO2 increased 
monotonically as distance increased from the top of the islet-containing alginate slab. Measured pO2 was maximal 
near the O2-permeable membrane, about 260 mmHg; pO2 decreased to a minimum of about 50 mmHg at the 
outer face of the slab.
The slope of the profile was lower near either boundary than in the center. This likely reflected the heterogene-
ous distribution of islets in the slab and the large islet size relative to the slab thickness. The center of a spherical 
islet could not be closer to either slab surface than a distance equal to its radius. Thus, these regions were depleted 
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of islet tissue relative to the core, thereby leading to a lower rate of oxygen consumption and a reduced rate of pO2 
decrease with distance.
Minimum required gas chamber pO2. A roughly constant quantity of islets was packed in disc-like slabs 
of successively reduced diameter. With increasing islet surface density, the pO2 gradient across the slab increased, 
resulting in lower values near the host-tissue interface. To compensate for the increased islet density, the gas 
chamber pO2 had to be increased. Because the pO2 drop across the oxygen-permeable membrane was estimated 
to be very small under the conditions of this study, we took the maximum measured pO2 in the slab to be the 
minimum value required in the gas chamber. Measured values of this parameter ranged from 190 to 305 mmHg 
for islet surface densities of 2,400 to 4,800 IEQ/cm2 (Table 1).
The implantable device was designed for O2 replenishment to be carried out every 24 hr. During this period, 
the pO2 in the gas chamber decreased as a result of oxygen consumption by islets and escape via diffusion through 
Figure 1. βAir device and system to measure oxygen profile within slabs. (A) Islet compartment with islets 
embedded in a 500–600 μm thick alginate slab reinforced on each side with a stainless steel grid, outer face 
overlain with alginate-filled PTFE membrane, which interfaces with host tissue, interior face covered by 
oxygen-permeable silicone rubber-PTFE membrane. (B) PEEK housing contained gas chamber and two ports 
connected to subcutaneously-implanted access ports. (C) Top view of βAir device with about 2,400 IEQ. Islet 
density was varied by varying diameter of islet chamber. (D) Top surface of devices with different islet densities, 
islets visible beneath top metal grid. Volume fraction of slab occupied by islets with about 2,400, 3,600, and 
4,800 IEQ/cm2 was 8.5, 12.7, and 17.0%, respectively, at slab thickness of 500 μm. (E) Oxygen profiles in islet 
compartment measured with modified βAir device (lacking alginate-filled membrane and top metal grid) 
placed in chamber, 37 °C, pO2 40 mmHg to simulate microvasculature). Device was immersed with very thin 
layer of medium over slab, gas chamber purged with mixtures at various pO2 (outlet port not shown). pO2 
microelectrode under control of micromanipulator inserted into slab, traversed in stepwise increments. (F) 
Typical oxygen profile within slab. About 2,400 IEQ with OCR of 3.5 pmol/IEQ/min immobilized in a 600-
μm alginate slab at a density of 4,800 IEQ/cm2. pO2 electrode was inserted at immobilized islet slab-medium 
interface and moved sequentially at increments of 100 μm down to the gas permeable membrane. Left Panel: 
Raw data. Right Panel: pO2 profile calculated from steady-state data in left panel.
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the encapsulating alginate. Therefore, the initial pO2 in the replenishment gas mixture was required to be higher 
than the measured minimum pO2 values summarized in Table 1. To determine the required initial pO2, devices 
loaded with about 2,400 IEQ at various densities were implanted in diabetic rats with different initial gas chamber 
pO2. The gas mixture in each chamber was replenished to its initial level after 24 hours. Just before O2 replenish-
ment, the pO2 in the gas chamber was measured. Table 1 summarizes the initial pO2 and average final pO2 after 
24 hr. The final value at each islet density equaled or exceeded the minimum gas chamber pO2 required, thereby 
ensuring that the initial pO2 levels used were sufficient to maintain the functionality of the islets.
Maintenance of islet viability. Measurements were made in a custom-made stirred cell (Fig. 2A) of 
islet oxygen consumption rate (OCR) in the alginate slab before implantation and after explantation (Fig. 2B). 
Recovery of initial OCR was 98, 82, and 89% for 2,400, 3,600, and 4,800 IEQ/cm2. For all 17 animals the average 
OCR recovery was 88%, which indicates that most of the initial viable islet tissue was maintained and very little 
viable tissue was lost during the implantation period.
Islet Density 
(IEQ/cm2)
Minimum pO2* 
(mmHg)
O2 partial pressure in the Gas 
Chamber** (mmHg)
Initial pO2
Final pO2 after 
24 hr
2,400 190 ± 31 304 190 ± 22
3,600 229 ± 57 456 280 ± 24
4,800 305 ± 34 570 350 ± 45
Table 1. Oxygen partial pressure in the gas chamber. *About 2,400 IEQ with OCR of 3.4–3.8 pmol/IEQ/min 
were immobilized at various densities, and a microelectrode was used to measure pO2 at different depths in 
the slab. Minimum pO2 is the lowest pO2 in the gas required to achieve 50 mmHg at the outer face of the islet-
containing alginate slab near the interface with host subcutaneous tissue. N = 3 experiments at each condition. 
**Devices containing islets at various densities were implanted into diabetic rats. The gas chamber was flushed 
every 24 hr with 20-ml gas mixtures containing specified oxygen concentrations, 40 mmHg CO2, and balance 
nitrogen. The pO2 in the gas chamber was measured at the beginning and after 24 hr, just prior to flushing with 
the fresh gas mixture. n ≥ 105 different measurements for each islet density as follows: n = 12 rats for 20 days, 10 
rats for 25 days, and 3 rats for 35 days, respectively, at islet densities of 2,400, 3,600, and 4,800 IEQ/cm2.
Figure 2. Oxygen consumption rate (OCR) of islets immobilized in alginate slabs. (A) Cross-sectional 
schematic diagram of device for measuring OCR of islets in alginate slabs. A magnetic stirring bar is driven by 
a magnetic stirrer motor (not shown). The conical chamber is filled with buffer, and pO2 is monitored by an 
oxygen microelectrode. OCR is determined from the rate of change of pO2 versus time. Pre-implantation OCR 
is determined with an islet-alginate slab prepared for this purpose containing about 250 IEQ of the same islets 
used in the device. The total OCR of the implanted slab is calculated from the measured OCR times the ratio of 
the number of IEQ actually implanted divided by the number of IEQ in the slab used for OCR measurement. 
Post-implantation OCR is determined from a sample of the islet-alginate slab carefully removed from the device 
after explantation. (B) OCR recovery after explantation of βAir devices. OCR is plotted before implantation and 
after explantation. n = 5, 9, and 3 for 2,400, 3,600, and 4,800 IEQ/cm2, respectively. The total OCR of the post-
implantation slab sample is calculated in a similar way using the number of IEQ in the post-implantation slab 
sample. Average OCR for naked islet preparations (n = 104) was 340 ± 80 nmol/(min mg DNA), equivalent to 
3.4 ± 0.8 pmol/(min IEQ), 1900 ± 400 nmol/(min cm3), and 32 ± 7 nmol/(s cm3).
www.nature.com/scientificreports/
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Prediction of minimum chamber pO2. A mathematical model was developed by use of a steady state 
mass balance equating the oxygen diffusion rate to the oxygen consumption rate in a differential slice of the 
slab in order to relate the design and operating parameters of the device. The minimum required oxygen partial 
pressure driving force, which is the difference between values in the gas chamber and at the host tissue interface, 
is plotted versus the islet volume fraction in the slab or, equivalently, the islet surface density, in Fig. 3. The predic-
tion of the model agreed well with the experimental data.
Maintenance of normoglycemia. Devices containing roughly 2,400 IEQ at four different surface densities 
were implanted in 137 rats. Islet function in implanted devices was assessed by monitoring glucose homeostasis. 
Almost all animals remained normoglycemic for different periods of time including 66 that remained normogly-
cemic for more than 8 weeks. Blood glucose concentration from devices in selected animals that were explanted 
for subsequent tests are plotted in Fig. 4A. One device was removed after the animal became hyperglycemic 
at 42 days post-implantation. All other animals remained normoglycemic until device explantation from 78 to 
238 days following implantation, after which blood glucose concentration rapidly rose to hyperglycemic levels. 
Normoglycemic periods of 6 months or more were observed in some animals with all surface densities.
Intravenous glucose tolerance tests. IVGTT data were obtained from 66 animals with implanted 
devices (Fig. 4B). The results when measured on day 20 and again on day 40 following implantation (Fig. 4B) were 
very similar to that of normal nondiabetic animals. There was no systematic significant difference between data 
for nondiabetic animals and animals with implanted devices having surface densities of 2,400, 3,600, and 4,800 
IEQ/cm2. There was a significant increase in blood glucose concentration at short times for animals with 1,000 
IEQ/cm2.
Correlation between normoglycemia time and islet quality parameters. Normoglycemia time 
in animals with implanted devices ranged from a minimum of none to a maximum of 229 days after elective 
explantation from an animal still normoglycemic. We hypothesized that variations in the quality of islet prepa-
rations immobilized in the devices accounted for at least part of this variation. Animals were assigned to groups 
having normoglycemia times of (1) none, (2) >0 to 4 wk, (3) 4 to 8 wk, or (4) >8 wk or time of explantation 
(always greater than 8 wk). The datum point for each animal is plotted on coordinates of number of IEQ ver-
sus pre-implantation OCR of the immobilized islets (Fig. 5A,B), and each axis is divided into three domains. 
Normoglycemia time increased with increasing IEQ and increasing OCR. The fraction of animals displaying 
long term (>4 wk) normoglycemia was 100% in the upper right domain and 0% at the lower left. Nearly 100% 
was observed for IEQ > 2,425; the same was true for OCR > 7,350 pmol/min. We normalized the data in terms 
of IEQ/kg and OCR/DNA (Fig. 5C,D) for comparison with results from a previous study18 with naked rat islets 
transplanted in mice, shown by the solid curve, which represents the predicted marginal islet mass based upon 
these quality parameters. The fitted curve from the previous study agreed with data from the current study. To the 
right of the curve, 69% of the animals were normoglycemic for >8 wk and 88% for >4 wk. To the left of the curve, 
only 33% were normoglycemic >4 wk, and 6% never attained normoglycemia.
Islet insulin content pre-implantation was also measured in all experiments. In contrast to IEQ and OCR, 
insulin content was not useful as an islet quality parameter. The Pearson correlation coefficient between mean 
blood glucose for 29–32 d after implantation and total insulin content was 0.06, indicating no correlation. Average 
Figure 3. Dependence of required final oxygen partial pressure difference on volume fraction islet tissue or 
islet surface density. Data points for S = 2,400, 3,600, and 4,800 IEQ/cm2 are from Table 1. Curve in red is 
prediction from Equation (5) calculated with Vmax = 3.2 × 10−8 mol/cm3 s, L = 600 μm, pL = 50 mmHg, and 
other parameters specified in Methods.
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normalized insulin content of 75 ± 40 mg/IEQ for implantations in the upper right domain in Fig. 5A was not 
significantly different from the value of 74 ± 30 mg/IEQ for implantations in all of the other eight domains, indi-
cating that the parameter was not predictive of transplantation outcome in this study.
Discussion
A native pancreatic islet is well vascularized, which results in nearly uniform oxygen concentration of 
38–40 mmHg throughout the islet18. In isolated islets, O2 must diffuse from the surface into the islet core; there-
fore, a higher concentration of O2 must be supplied on the surface of an islet. The subcutis (SC) is an attractive 
Figure 4. Long-term function of implanted devices with islets encapsulated at various surface densities. (A) 
Blood glucose concentration plotted versus time after implantation. βAir devices implanted with about 2,400 IEQ 
at surface densities of about 1,000, 2,400, 3,600, and 4,800 IEQ/cm2 into streptozotocin-induced diabetic rats. 
Data from devices with 1,000 IEQ/cm2, which were replenished with atmospheric air, are from an earlier study10 
and are shown for comparison. Data for other devices, which were replenished with gas mixtures having initial 
pO2 shown in Table 1, are taken from the experiments plotted in the upper right domain of Fig. 5A, for which 
IEQ ≥ 7350 and OCR ≥ 2425. Blood glucose concentration for each symbol represents mean of non-fasting 
measurements over 5 d taken at 7 am and 4 pm each day (total of 10 measurement for each animal). On day 0, 
insulin sustained-release capsules were removed. (Data for blood glucose immediately after implantation of these 
capsules not shown). Thirty devices electively explanted from 42 to 229 d after implantation, indicated by arrows, 
all but one of which were normoglycemic at time of explantation. n = 2 or higher designates multiple devices 
treated identically, the results of which were averaged. (B) Intravenous glucose tolerance test (IVGTT) performed 
on day 20 and day 40 following implantation. Data summarized for diabetic rats (n = 28), non-diabetic rats 
(n = 52), and diabetic rats having device implanted with different surface densities (n = 66). Latter group 
included all animals that were normoglycemic for 8 weeks or more. IVGTT data plotted for animals having 
devices with about 1,000 IEQ/cm2 and for combined data for devices with 2,400, 3,600, and 4,800 IEQ/cm2. For 
surface densities of about 1,000 IEQ/cm2, day20: 0 to 120 min (n = 9), 0 to 180 min (n = 1); day 40: 0 to 120 min 
(n = 9), 0 to 180 min (n = 0). For 2,400, 3,600, and 4,800 IEQ/cm2, respectively, 0 to 180 min, day 20: n = 27, 19, 
and 8; day 40: n = 26, 15, and 5.
www.nature.com/scientificreports/
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site for transplantation because of the simplicity of implantation. However, the O2 level in the SC is only about 
40 mmHg, which is insufficient to fully support islets above about 100 µm in diameter19 and will lead to delete-
rious effects on insulin secretion4,15 from human islets that typically average about 150 µm diameter. Attempts 
to implant macroencapsulated islets that rely on oxygen supply from the surrounding tissue eventually fail to 
achieve prolonged satisfactory function except for one report with a monolayer device20. Encapsulation of islets 
exacerbates oxygen supply limitations, which leads to degradation of islet glucose-dependent insulin secretory 
capability and loss of viability.
We have used a retrievable, macroencapsulated planar diffusion chamber for subcutaneous islet implantation 
in a rat in which exogenous oxygen is supplied by diffusion from a gas chamber to one side of an alginate-islet 
slab. We explored the relationship between increased surface density of encapsulated islets and the initial pO2 
required in the gas chamber to ensure that at the end of 24 hr, just prior to replenishment, the minimum pO2, at 
the surface of islets nearest the host-device interface would be about 50 mmHg or greater, thereby ensuring that 
the islets remain fully viable and functional.
We made in vitro measurements of the pO2 profile in the alginate-islets slab and of pO2 changes in the gas 
chamber to estimate the approximate required pO2 in the gas mixture (Table 1). For example, to support the 
Figure 5. Relationship between normoglycemia time and islet parameters of animals for which pre-implant 
data is available. Time period during which normoglycemia was maintained: (1) none, (2) >0–4 wk, (3) 4–8 
wk, and (4) 8 wk or explantation while still normoglycemic. (A) Datum point for each animal plotted at its 
corresponding OCR and number of IEQ. Data field is segregated into nine regions defined by IEQ ≤ 2050, 
2050 ≤ IEQ ≤ 2425, and 2425 ≤ IEQ; OCR ≤ 5850, 5850 ≤ OCR ≤ 7350, and 7350 ≤ OCR. (B) Fraction of 
normoglycemia times <4 wk (top two symbols) and >4 wk (bottom two symbols) indicated within each region. 
Average for each row and column is also tabulated in bold. (C) Same data as in (A) plotted on coordinates of 
IEQ/kg and OCR/DNA. DNA content was calculated using 1,560 cells/IEQ13 and 6.5 mg DNA/cell17. Solid curve 
was fitted to data for naked transplantation of rat islets into mice18, given by log10 y = ax + b, where y = IEQ/kg,  
x = OCR/DNA in nmol/min mg DNA, a = 0.00515 DNA/OCR, and b = 5.45. Dashed lines to left and right 
of fitted curve are 68% confidence limits associated with fitted curve. (D) Same as (C), with the fraction of 
normoglycemia time <4 wk (top) and >4 wk (bottom) indicated for each region.
www.nature.com/scientificreports/
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highest density tested of 4,800 IEQ/cm2, a minimum pO2 of about 305 mmHg was needed. An initial gas chamber 
pO2 of 570 mmHg dropped after 24 hr to about 350 mmHg. Thus, an initial pO2 of 570 mmHg was sufficient to 
support all islets at a density of 4,800 IEQ/cm2. Because the minimum pO2 levels required in the gas chamber are 
much higher than that in the microvasculature, this result could not have been achieved by any other method that 
relies upon the local oxygen supply through the bloodstream, even if extensive neovascularization surrounding 
the implant had been achieved.
Nearly all of the viable islets initially implanted in the device retained their viability throughout the duration 
of these experiments, even at the highest density of 4,800 IEQ/cm2, as demonstrated by high OCR recovery at 
explantation (Fig. 2). The small reduction in OCR for explanted islets may have resulted in part, from normal islet 
turnover21. To our knowledge, this is the first report of quantitative data demonstrating long-term maintenance 
of islet viability following naked or encapsulated transplantation. We assumed that total OCR is a measure of the 
amount of viable tissue, but we cannot conclude that OCR/cell remained constant or perhaps increased, without 
data for the number of cells in each slab tested22.
We previously employed a complex, detailed numerical model to explore the interaction of oxygen diffusion 
and consumption in assemblages of spherical islets dispersed in an alginate slab17 in order to predict conditions 
required to maintain islet viability and function. Here we employed a simpler model amenable to analytical solu-
tion that treated the slab as a homogenous medium characterized by effective properties derived using those of 
the individual phases. To our knowledge, this is the first attempt to predict the behavior of experimental data 
obtained with a real encapsulation system. The remarkable agreement between prediction and data (Fig. 3) val-
idates the mechanism and hypothesis upon which development of the device is based as well as the parameter 
values employed. Furthermore, the equations that result from the analytical solution, which can also be derived 
for all other basic geometries, such as cylinders and spheres, provide a simple design framework that relates the 
oxygen partial pressure driving force, device geometry and dimensions, islet tissue loading (in terms of islet vol-
ume fraction or surface density), islet OCR, and oxygen permeability of islets and alginate. This framework pro-
vides a powerful tool for translation to the clinic of devices with new designs incorporating (1) larger amounts of 
islet tissue, (2) islets of different species, such as porcine, and (3) differentiated pluripotent cells that have different 
OCR and islet secretion properties.
Most devices containing 2,400 IEQ at densities up to 4,800 IEQ/cm2 implanted into diabetic rats main-
tained normal fasting blood glucose for 4 wk or more. In animals normoglycemic for 8 wk or more or until 
elective termination of the experiments up to 229 days after implantation (Fig. 2A), no detectable delay in the 
near-normal IVGTT was observed (Fig. 2B), demonstrating fast response of the device implant in the subcutis 
of a rat. Normalization of IVGTT by itself does not prove that the islets are functioning normally. As long as the 
tissues, in particular the liver and muscle, are well insulinized, glucose can be controlled even though the timing 
of insulin release from encapsulated islets is abnormal23. Nonetheless, islets immobilized at very high densities in 
the alginate slab survived in the βAir device for a long period of time without deterioration of glucose control and 
without apparent damage from exposure to pO2 levels greater than physiologic.
Normoglycemia time varied widely between different implantations under otherwise identical conditions. 
This variation correlated with islet quality parameters IEQ and OCR24, which emphasizes the importance of 
initial islet quality in determining the outcome of each transplantation. When expressed as normalized param-
eters IEQ/kg body weight and OCR/DNA, our results were comparable to an earlier study with naked rat islets 
transplanted into mice25. Scatter along the OCR/DNA axis may have been amplified because DNA was calculated 
from IEQ measurements made visually, which themselves are subject to significant scatter26. Healthier islet prepa-
rations with higher OCR survived for long periods with little loss of viable tissue while maintaining normoglyce-
mia. Under the same implantation conditions, islets with reduced OCR, which indicates mitochondrial damage 
and possibly continued ongoing cell death processes at the time of transplantation, resulted in shorter periods 
of normoglycemia (Fig. 5). The poorer quality islet preparations did not improve when implanted in vivo in the 
device. In the field of organ preservation, use of perfusion circuits to mimic healthy physiologic conditions have 
been suggested as a means to allow organs to recover from cellular stress and tissue injury during donor death 
and organ procurement27. Our findings suggest that islets isolated using current methods would not benefit from 
such an approach.
An important finding of this study is that the size of a device for implantation in humans can be substantially 
reduced. Consequently, for example, a dose of 250,000 IEQ could be supported under these conditions in a device 
having about 50 cm2 surface area for supply of O2 from the gas chamber. By mating two islet compartments back 
to-back with a sandwiched gas chamber, the surface area required for islet support could be farther reduced 
to 25 cm2, which is achieved by a disk with a diameter of 5.6 cm or about 2 ¼ in. A dose of 500,000 IEQ would 
require two such devices or a single device with 8.0 cm diameter. Such size reduction would make implantation 
in humans more feasible.
In addition to reduction of implanted device size, these findings suggest substantial benefits in comparison 
to naked islet transplantation. Human islet transplantation requires about 10,000 or more IEQ/kg body weight, 
often supplied from two or more cadaveric donors28. Studies in mice29 and in clinical islet transplantation30,31 
indicate that only a fraction of the islet dose survives the implantation and early engraftment period. In contrast, 
our results demonstrate that enhanced in situ supply of exogenous oxygen directly to islets encapsulated at high 
densities can maintain viability and function of the islets with only a small loss over long periods of time. By 
eliminating the substantial loss of viability and function currently experienced, the limited supply of islets can be 
used much more efficiently, and human preparations normally discarded because of insufficient numbers of islets 
might be used fruitfully.
Minimization of islet cell death may also enhance the immunoprotection provided by encapsulated alginate in 
the case of stimulation of the indirect pathway, which mediates rejection of xenografts and may also be operative 
with allografts32. Host antigen-presenting cells take up graft proteins and peptides released from the encapsulated 
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cells and present donor-derived peptides on host MHC molecules to host T-cells. The extracellular domain of 
many cell surface and membrane-anchored proteins is normally released by proteolysis to produce shed anti-
gen33,34, some of which may be small enough to permeate across an immunobarrier material such as alginate 
hydrogel. The rate of antigen release is sharply increased when peptides are released from the interior of dying 
cells35–37. Hence, the presence of dying cells in encapsulated islets may generate a large immunogenic stimulus, 
especially with xenografts, which triggers the indirect pathway and ultimately leads to attack by agents released 
from activated immune cells that form a florid response around the implant. By maintaining the viability of 
virtually all islets encapsulated in the βAir device, development of this immunogenic stimulus is prevented, and 
immunoisolation can be attained. This mechanism may have played an important role in the previous demonstra-
tions with the device of successful xenotransplantation in minipigs12 and allotransplantation in a human13, both 
without immunosuppression.
Here we show long-term quantitative preservation of islet viability and function after transplantation in a 
retrievable macroencapsulation device containing islets in an alginate slab bounded on one face by supraphysio-
logical levels of oxygen. Islet densities as high as 4,800 IEQ/cm2 are maintained viable and functional with initial 
gas chamber pO2 of 570 mmHg. To our knowledge, this is the first successful demonstration of implantation with 
such a high tissue density. Use of a novel OCR assay before implantation and after explantation shows nearly 90% 
preservation of islet viability. This is the first report of quantitative preservation of islet viability with any encap-
sulation system. The same benefits will accrue to xenogeneic islets and to islet cells derived by differentiation of 
stem cells. The results reported here indicate that the enhanced oxygen supply in the βAir device provides a suit-
able approach for treating diabetes with encapsulated islets and for other cell therapies in humans. In addition, 
the simple mathematical model provides a framework for design of clinical devices based on device operating 
conditions and tissue properties.
Materials and Methods
Animals, diabetes induction, and pre-treatment. Lewis rats (260–280 g) were purchased from 
Harlan (Rehovot, Israel), and diabetes was induced by a single intravenous infusion of 85 mg/Kg body weight 
of Streptozotocin (STZ; Sigma, Israel) as previously described10. Animals had free access to food at all times and 
were considered diabetic when non-fasting blood glucose exceeded 450 mg/dl for 4 consecutive days or more. 
To prepare the diabetic animals for device implantation in a non-stressing, close-to-normal blood glucose envi-
ronment, 1.5 capsules of a sustained release insulin implant (Linplant, LinShin, Toronto, Canada) were inserted 
under the skin of the diabetic animals, which were considered ready for implantation of the device when their 
non-fasted blood glucose was under 250 mg/dL for 3 consecutive days or more. The sustained-release insulin 
capsules were removed 48 hr after device implantation, leaving the encapsulation device as the only source for 
insulin. The efficacy of glycemic control was followed after implantation by assessing the functionality of the 
islets in the device through twice daily measurements of non-fasting blood glucose concentration. Animals were 
sedated, blood samples were collected from the tail, and glucose levels were measured by glucometer (Accu-Chek 
sensor, Roche Diagnostics GmbH). Blood glucose concentration ≤200 mg/dl was deemed to be normoglycemic. 
Intravenous glucose tolerance tests (IVGTT) were performed 21 and 42 days post-transplantation as follows: 
animals were fasted overnight. On the following morning, 1 ml of 0.7 M glucose solution was infused within 
10–15 sec (dose of 500 mg/kg BW), and blood glucose samples were collected for measurement before infusion 
and at 10, 30, 60, 120 and 180 min following glucose infusion. Selected devices were electively explanted from 
normoglycemic animals for further study at times ranging from 42 to 238 days post-transplantation.
Islet isolation and culture. Pancreata from 9 to 10-week old male Lewis rats weighing 260–280 g under-
went collagenase digestion following a standard procedure with slight modification, as described previously10. 
Briefly, each pancreas was infused with 10 ml enzymatic digestive blend containing 15 PZ units of collagenase 
NB8 (Serva, Heidelberg, Germany) and 1 mg/ml bovine DNAse (Sigma, Israel) dissolved in HBSS solution 
(Bet-HaEmek, Israel) for 14 min. Islets were purified on discontinuous Histopaque gradient (1.119/1.100/1.077 
in RPMI) run for 20 min at 1,750 × g and 6 °C, washed twice, and cultured in complete CR medium (1:1, 
CMRL:RPMI medium, Bet HaEmek, Israel), supplemented with 10% fetal bovine serum (Bet-HaEmek, Israel) 
for 1 wk prior to being integrated in implantable devices. Measurement of islet size and number in a preparation, 
from which islet volume and number of IEQ were determined, was carried out by visual counting as previ-
ously described10. Insulin content of islets was measured with acid/ethanol extraction and ELISA (ThermoFisher 
Scientific). Islet purity estimated visually was always greater than 95%. Naked islet viability, assessed as the frac-
tion of green cells measured with the Acridine Orange/Propidium Iodide membrane integrity assay was always 
greater than 95%.
The βAir device. The subcutaneously-implantable device, named βAir10, had an external disc-shaped hous-
ing made of clinical grade polyether ether ketone (PEEK Optima LT1R40; Invibio, Lancashire, UK) with a diam-
eter of 31.3 mm and thickness of 7 mm (Fig. 1). The device consisted of three major components: (1) The islet 
compartment contained about 2,400 IEQ embedded in 500 to 600-µm thick ultrapure high guluronic acid algi-
nate, reinforced with 100-µm thick stainless steel grids having about 80% fractional open area (top grid, Fig. 1A, 
inset, Suron, Maagan Michael, Israel), glued to the PEEK housing with medical epoxy adhesive (Epotek 301–2, 
Epoxy Technology Inc., Billerica, MA, USA). Mechanical support was provided by the bottom grid, identical to 
the top grid, which was placed under the gas permeable membrane and reinforced by PEEK mechanical supports 
(Fig. 1B). To vary islet surface density, 2,400 IEQ were immobilized in a slab with a diameter of 11.3, 9.3, or 
8.0 mm, resulting in densities of 2,400, 3,600, or 4,800 IEQ/cm2 en face surface area for oxygen transport, respec-
tively (Fig. 1B,C). (2) The gas chamber (3-ml volume) was separated from the islet compartment by a 25-µm 
gas-permeable silicone rubber-teflon membrane (Silon, BMS, Allentown, PA) and contained inlet and outlet gas 
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chamber ports connected by two polyurethane tubes to subcutaneous access ports (Cat. No. PMINO-PU-C70, 
Instech Solomon, PA) implanted under the skin at a site remote from the device, as previously described10. (3) A 
25-µm, 0.4-µm pore diameter hydrophilized microporous polytetrafluoroethylene (PTFE) membrane (Biopore, 
Millipore, Billerica, MA), separated the islet module from host tissue and protected the islets from the cellular 
part of the immune system. Devices with a diameter of 18 mm were used to give islet densities of 1,000 IEQ/cm2. 
Some of these devices made use of an earlier, less effective design10 and the results are provided here selectively 
for comparison.
Device assembly. An average dose of 2,400 ± 200 IEQ (range 1,700–3,300 IEQ) was collected by 5-min sed-
imentation. The pellet was gently mixed with 2.2% (w/v) ultrapure high-guluronic acid (68%) alginate (Pronova 
UPMVG, Novamatrix; Sandvika, Norway). The mixture was placed in the islet module compartment and spread 
through the openings of the top grid (Fig. 1A, inset) with the tip of a long-nosed Pasteur pipette. The microporous 
PTFE (Biopore) membrane was then fixed onto the device using a Viton O-Ring (hardness 75 Shore and outer 
diameter 27 mm, McMaster Carr, Aurora, OH) and sealed to the plastic housing with medical silicone adhesive 
(MED 2000, Polytek Easton, PA). The alginate was cross-linked by applying a flat sintered glass disc (Pyrex, UK) 
saturated with strontium chloride dissolved in RPMI medium for a final concentration of 70 mM. The device and 
sintered glass were immersed in the RPMI-strontium medium for 16 min, resulting in a 500- to 600-µm thick 
coin-like slab. The thickness variations originated with variation in glue thickness. The device was washed for an 
additional 5 min at 37 °C in complete CR medium (Beit HaEmek, Israel). Fully fabricated devices were washed in 
complete CR medium at 37 °C with agitation for 2 h before implantation.
Device implantation. All animal experiments were performed in strict accordance with the Institutional 
Animal Care and Use Committee Guidebook. The study was approved by The Council for Experiments on 
Animal Subjects, Ministry of Health, Israel (Permit No. IL05-05-012). All efforts were made to minimize ani-
mal suffering. Rats were anesthetized by intraperitoneal injection of 90 mg/Kg Ketamine and 10 mg/Kg Xylazine 
followed by isoflurane inhalation. A 3-cm incision was made for the device on the dorsal skin, and muscles were 
separated from the hypodermis. A second incision was made in the skin between the shoulder blades, and two 
channels connecting this site with the device implantation site were created by traversing 3-mm wide stainless 
steel needles under the skin. The device was inserted under the dorsal skin incision with the islet module facing 
the fascia, and the gas chamber ports were connected to the remote subcutaneous access ports. The skin was 
sutured and fixed with a tissue adhesive (Histoacryl, Tufflingen, Germany). Devices were implanted into 141 
animals. Data was discarded from four animals due to mechanical problems with the device.
Gas mixture replacement. Every 24 h the animal was sedated with isoflurane inhalation. A 27G needle was 
inserted into each of the two implanted access ports, and the gas chamber was purged with 20 ml (about 6.7 cham-
ber volumes) of gas mixture containing the specified pO2, 40 mmHg CO2, and balance N2. Final total pressure in 
the gas chamber was equal to ambient atmospheric pressure. To obtain the different oxygen mixtures, prefilled 
cylinders were used (Maxima, Israel).
Islet oxygen consumption rate (OCR). OCR of naked islets was measured as described previously10. 
Measurements were also made with an immobilized aliquot of 250 IEQ from the preparation to be transplanted in 
the device and with the islet alginate slab after device explantation. The preimplant islet sample was immobilized 
in 30 μL of high guluronic acid alginate shaped as a coin with a thickness of 500 μm and diameter of 8.7 mm. After 
elective explantation of a device, the alginate slab containing the islets was carefully removed. The number of IEQ 
(≥200 islets) in a small defined surface area was quickly determined by manual counting under a microscope. The 
slab having the largest diameter was cut into a smaller piece that fit into the measurement chamber. The pre- or 
post-implant slab was placed on a glass slide, a 5-mm diameter magnetic stirrer bar was placed on top of the slab, 
and the assembly was covered with a conical OCR measurement chamber (Fig. 2). The conical chamber was filed 
with 1:1, CMRL:RPMI medium containing 1% (v/v) fetal bovine serum to a final volume of 620 µl. The chamber 
was equipped with Clark-type oxygen electrode of 500-µm diameter connected to a picoammeter controller 
(Cat No. PA2000, Unisense, Arhaus, Denmark). The O2 measurement chamber was placed within a Perspex box 
with the air temperature maintained at 37 ± 1 °C using a temperature control unit (Eurotherm 808; Eurotherm 
Worthing, UK). The stirring speed was increased until measured OCR did not change (about 70 rpm), thereby 
assuring minimal effects associated with mass transfer boundary layers around the islets and the O2 electrode. No 
damage to the alginate slab or the islets was observed as assessed by islet and slab morphology and stable OCR 
readings. The electrode was calibrated using medium equilibrated with gas containing zero or ambient air oxygen 
concentrations. The O2 level in both phases are reported here as oxygen partial pressure pO2, in units of mmHg, 
which is related to oxygen concentration c by the equation c = αpO2, where α is the Bunsen solubility coeffi-
cient, 1.34 × 10−9 mole/(cm3mmHg) for oxygen in medium at 37 °C. Consequently, for example, at steady-state 
ambient O2 partial pressure of 160 mmHg (21% O2, 1 atm), dissolved O2 concentration is 215 µM in the medium 
at 37 °C. As a result of the O2 consumption by the islets, the O2 concentration in the medium within the conical 
measurement chamber decreased with time from its initial value in equilibrium with ambient air. The data for O2 
concentration versus time was fitted by linear regression, and the slope was used to estimate OCR of the islets38. 
Data was used between 160 and 80 mmHg, which yielded the highest slope. Estimation of OCR by this method 
required that the pO2 profiles within the slab were in quasi-steady state and that the pO2 difference between the 
medium and the slab interior was small. Approximate theoretical analysis similar to that previously used for OCR 
measurement with microencapsulated islets39 indicated that these conditions were met for the measurements 
made in this study.
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Oxygen gas measurements. To measure O2 concentration in the gas chamber within the implanted 
devices, a 27G needle connected to 1.0 ml syringe was inserted into one of the implanted subcutaneous access 
ports, and a 250-µl sample was taken from the gas chamber 24 hr after the last O2 replenishment and injected into 
the conical measurement chamber. The change in the electrode measurement was used to calculate the oxygen 
concentration in the sample from the gas chamber. The O2 electrode was calibrated with gas mixtures having pO2 
of zero (pure N2), 160 mmHg (ambient air), and 304 mmHg.
Oxygen profile across the islet slab. About 2,400 IEQ were immobilized at various densities as described 
for βAir device assembly, but without the PTFE (Biopore) membrane and without the metal grid on top. The 
device was placed in a covered 90 mm Petri-dish, overlain with RPMII medium so as to create a layer of mini-
mal depth on top of the device, and the space above the slab was purged with a gas stream having 40 mmHg O2, 
40 mmHg CO2, and 680 mmHg N2 (Fig. 3), which simulated the gas composition in the subcutis. The gas chamber 
was purged with oxygen concentrations varying between 152 and 305 mmHg. An O2 electrode with a diameter 
of 500 µm, attached to a micromanipulator, was inserted into the islet-containing slab and advanced at 100 µm 
increments from the distal side of the islet slab downwards toward the gas permeable membrane. At each step, 
the O2 electrode readings reached a steady-state level before moving to the next step. The entire measurement 
system was located in a 37 °C chamber. Although the presence of the electrode would disturb the O2 field between 
the surface of the oxygen-permeable membrane and the face of the electrode, the pO2 measurement of primary 
interest here was the minimum value farthest from the gas chamber where the electrode first entered the slab. 
Under these conditions, the error incurred in determining if the pO2 is about 50 mmHg is expected to be small.
Mathematical model of oxygen diffusion and consumption in islet-alginate slab. We consider a 
one-dimensional slab of thickness L containing a heterogeneous medium of islets dispersed in alginate. Oxygen 
concentration c is linearly proportional to oxygen partial pressure p according to c = αp, where α is the Bunsen 
solubility coefficient. At the slab face next to the gas chamber, x = 0 (the small effect of the Silon membrane is 
ignored), the oxygen partial pressure is set at p0. At the slab surface that interfaces with host tissue, we assume the 
most conservative case that all oxygen is supplied by the gas chamber, and the interface is taken to be imperme-
able to oxygen. We set the oxygen partial pressure at this surface, x = L, as pL = 50 mmHg, to be consistent with 
experimental conditions, in which case the oxygen consumption rate can be assumed constant at Vmax40. Under 
these conditions, a steady state oxygen mass balance equating the rate of diffusion to the rate of consumption 
across a differentiated slice of the slab can be written as
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Evaluating Equation (4) at x = L yields a relation between the required oxygen partial pressure difference and 
the other variables.
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or an expression for the maximum thickness possible for prescribed operating conditions.
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Noting that islet surface density S can be expressed by
φ
=S L
V (7)IE
where VIE is the volume of an IEQ (1.77 × 10−6 cm3/IEQ), Equation (6) can be rearranged to express the maxi-
mum surface density attainable
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Statistics. Data are expressed as mean + standard deviation. Statistical significance (p < 0.05) was deter-
mined by Student’s t-test.
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